3-FPM

Standard Drug Panel Inclusion

3-FPM (3-Fluorophenmetrazine) is a fluorinated phenylmorpholine stimulant that is not detected on standard 5-panel or 10-panel immunoassay drug screens. Its morpholine ring structure is distinct from amphetamines, and cross-reactivity with amphetamine immunoassays is not expected. No extended panels include phenylmorpholine compounds.

Urine Detection

3-FPM and its metabolites can be detected in urine for approximately 2 to 4 days after use. The primary metabolic pathways include hydroxylation, N-dealkylation, and ring-opening of the morpholine moiety. Standard immunoassay screens do not detect 3-FPM. A notable clinical concern is that chronic high-dose use of 3-FPM has been associated with a distinctive "3-FPM flu" syndrome, but this does not affect detection methodology.

Blood and Saliva Detection

Blood concentrations of 3-FPM are detectable for approximately 12 to 36 hours. Oral fluid testing can detect the parent compound for a similar window. Neither testing modality routinely includes phenylmorpholine compounds.

Hair Follicle Detection

Hair follicle analysis for 3-FPM requires custom LC-MS/MS methods. Standard commercial hair testing panels do not include phenylmorpholine compounds. Detection in hair is theoretically possible for up to 90 days.

Confirmatory Testing

LC-MS/MS and GC-MS are effective for identifying 3-FPM in biological specimens. The morpholine ring produces characteristic fragmentation patterns distinct from amphetamines, cathinones, and phenidates. Reference standards are available from forensic chemistry suppliers.

Reagent Testing

Marquis reagent typically shows no reaction or a faint yellow with 3-FPM. Mecke and Mandelin reagents show no significant reactions. The absence of color changes with common reagents distinguishes 3-FPM from most amphetamines, cathinones, and MDMA-like compounds. Reagent testing cannot positively identify 3-FPM but can help rule out common adulterants and substitutions.

Never Insufflate or Inject

The most critical harm reduction point for 3-FPM: do not insufflate it. Multiple community members have documented significant nasal damage from insufflation. The burning is severe, mucosal damage is cumulative, and there is no technique to adequately mitigate it. Oral administration is the only sensible route.

Oral Dosing Guidelines

Community-reported oral doses:

• Threshold: 10–15 mg
• Common: 20–40 mg
• Strong: 40–60 mg

A Reddit post on functional use tips for 3-FPM is one of the higher-quality community harm reduction resources, recommending starting at 20mg and assessing over 90 minutes before considering any supplementary dose.

Timing Is Critical

With 6–10 hour duration, 3-FPM taken after noon risks significant sleep disruption. Reddit discussions on "dose now and sleep later, or sleep now and dose later" reflect real community experience with this dilemma — sleep deprivation compounds the risks of stimulant use substantially.

Non-Responders and Batch Variability

Community posts about "3-FPM non-responders or just shitty batches" highlight that individual response varies significantly and batch quality affects potency. Start low with any new batch.

Dangerous Combinations

• MAOIs — Absolute contraindication
• Other stimulants — Additive cardiovascular and CNS risk
• Serotonergic medications — Review potential interactions before combining
• Alcohol — Masks stimulant effect, leads to inadvertent over-intoxication

Limit Frequency

Multiple Reddit discussions reflect community experience with frequency-escalating use patterns. Limit to once or twice weekly at most; daily use produces tolerance and psychological dependence.

Acute Toxicity

No formal human toxicity studies exist. Acute risks based on its dopamine/norepinephrine releasing mechanism include cardiovascular effects (elevated heart rate, blood pressure, arrhythmia risk at high doses), hyperthermia, and potential for stimulant toxidrome at overdose.

Causticity and Mucosal Damage

A significant and well-documented harm unique to 3-FPM is its causticity to mucous membranes. Multiple Reddit reports describe severe nasal and oral burning, damaged nasal passages, and persistent irritation from insufflation. One Reddit post is explicitly titled "Holy damn, did I underestimate 3-FPM's causticity." Another community post titled "Made an idiotic mistake injecting" describes intravenous use resulting in serious local tissue damage. These reports collectively establish that 3-FPM should never be insufflated or injected.

Cardiovascular Risk

Reports include discussion of cardiac concerns with 3-FPM. As a sympathomimetic releasing agent, tachycardia, palpitations, and blood pressure elevation are expected. Heavy use creates cumulative cardiovascular stress.

Brain Damage Concerns

A Reddit post specifically titled "3-FPM possible brain damage" reflects community-level concern about potential long-term cognitive effects — likely relating to dopaminergic neurotoxicity concerns general to heavy stimulant use rather than a specific 3-FPM-unique mechanism. Current evidence does not establish 3-FPM-specific neurotoxicity, but the general risks of heavy dopaminergic stimulant use apply.

Serotonergic Interactions

Posts discussing long-term 3-FPM use and serotonergic drugs reflect community awareness of potential interactions with serotonergic medications (SSRIs, etc.). The mechanism is incompletely characterized but warrants caution.

International Legal Status

3-Fluorophenmetrazine (3-FPM) is a fluorinated analogue of phenmetrazine (Schedule II under the 1971 UN Convention on Psychotropic Substances). 3-FPM itself isnot currently scheduled under any UN convention, though it was critically reviewed by the WHO Expert Committee on Drug Dependence (ECDD) at its 43rd meeting in 2020 . The ECDD found evidence of clandestine manufacture, public health risk, and no recognized therapeutic use, but it has not yet been placed under international control.

United Kingdom: Banned since May 2016 under thePsychoactive Substances Act (PSA), which broadly prohibits any substance capable of producing a psychoactive effect that is not specifically exempted. Prior to the PSA, 3-FPM was sold openly as a "legal high" in the UK and was identified in several fatality cases .

Germany: Controlled under theNeue-psychoaktive-Stoffe-Gesetz (NpSG) since November 2016 as a phenethylamine-derived substance falling within the act's structural group definitions . The NpSG bans trade and supply but does not criminalize simple possession for personal use.

France: 3-FPM isnot explicitly listed on France's controlled substances schedules as of 2025. However, French authorities identified 3-FPM on their market as early as 2015, and it could potentially be controlled under evolving NPS (new psychoactive substances) framework legislation .

Sweden: Classified as a controlled substance (narcotic) since 2015 .

Hungary and Switzerland: Both countries have specifically banned 3-FPM .

United States: Not specifically scheduled. As an analogue of phenmetrazine (Schedule II), potential prosecution under theFederal Analogue Act is theoretically possible but untested in case law for this specific compound .

Other jurisdictions: Controlled in Estonia. First identified on European drug markets in 2014 (Hungary, Sweden, UK) and subsequently detected in Croatia, Czech Republic, Denmark, France, Germany, Lithuania, Norway, Romania, Slovenia, and Spain by 2015 .

References

WHO. Critical Review Report: 3-Fluorophenmetrazine. 43rd ECDD. 2020. Psychoactive Substances Act 2016. UK Public General Acts. c.2. Neue-psychoaktive-Stoffe-Gesetz (NpSG). Bundesgesetzblatt. 2016. 21 U.S.C. SS 813 — Federal Analogue Act. United States Code.